All In Biotech

Free tool

FAERS Monitor: Fruzaqla

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217564 or its brand name (Fruzaqla, Fruquintinib). Reports on generic versions are filed under their own applications.

Reports

3,941

Serious

3,790

96% of reports

Hospitalization

1,205

Death reported

1,270

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death861
  • fatigue482
  • colorectal cancer metastatic396
  • colon cancer381
  • diarrhoea289
  • blood pressure increased272
  • decreased appetite249
  • asthenia246
  • myelosuppression244
  • dysphonia213
  • hypertension199
  • off label use190
  • nausea189
  • pain155
  • palmar-plantar erythrodysaesthesia syndrome133

Reports by year received

View as table
YearReports
20196
202011
20215
202217
202359
20241,193
20251,820
2026830

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,218 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
colorectal cancer metastaticSignal3961070.4965.4351,613
colon cancerSignal381140.0127.151,139
myelosuppressionSignal24436.432.28,321
palmar-plantar erythrodysaesthesia syndromeSignal13330.625.93,763
dysphoniaSignal21319.517.13,717
blood pressure increasedSignal2729.58.52,074
decreased appetiteSignal2495.75.1976
deathSignal8615.35.03,157
hypertensionSignal1995.04.4642
astheniaSignal2463.53.1443
fatigueSignal4823.33.0802
diarrhoeaSignal2892.42.1239
pain1551.31.214
nausea1891.31.111
off label use1901.21.04

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.